<DOC>
	<DOCNO>NCT00384774</DOCNO>
	<brief_summary>This study evaluate efficacy range intravenous dose COL-144 treatment migraine headache order select dose range study .</brief_summary>
	<brief_title>A Placebo-Controlled Adaptive Treatment Assignment Study Intravenous COL-144 Acute Treatment Migraine</brief_title>
	<detailed_description>This study set : - evaluate efficacy ( headache response two hour ) range intravenous dos COL-144 order select dose range evaluation , - explore time course effect range dose level COL-144 feature migraine include : headache response , proportion patient pain-free , headache recurrence , nausea , photophobia , phonophobia , disability , use rescue medication , patient global impression vomit - explore safety tolerability range dose COL-144 term adverse event , physical exam , vital sign , laboratory evaluation , ECGs - determine key PK parameter COL-144 explore relationship PK COL-144 time course extent clinical response</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Patients migraine without aura fulfil IHS diagnostic criterion 1.1 1.2.1 ( 2004 ) History migraine least 1 year Migraine onset age 50 year History 1 8 migraine attack per month Male female subject age 18 65 year Female patient childbearing potential must use highly effective form contraception ( eg combine oral contraceptive , IUD , abstinence , vasectomized partner ) Able willing return clinic treatment within 4 hour onset migraine headache Able willing give write informed consent History life threaten intolerable adverse reaction triptan Use prescription migraine prophylactic drug Pregnant breastfeed woman Women childbearing potential use highly effective contraception History evidence coronary artery disease , ischemic hemorrhagic stroke , epilepsy condition place patient increase risk seizure History hypertension ( control uncontrolled ) Sitting BP &gt; 160mmHg systolic &gt; 90mmHg diastolic 2 repeat measurement screen Current use hemodynamically active cardiovascular drug History within previous 3 year current evidence abuse drug , prescription illicit , alcohol Significant renal impairment Previous participation clinical trial Participation clinical trial experimental drug device previous 30 day Any medical condition laboratory test judgment investigator make patient unsuitable study Relatives , staff directly reporting , investigator Patients know hypersensitivity COL144 , 5HT1F receptor agonist excipient COL144</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Migraine</keyword>
</DOC>